Institutional implementation of clinical tumor profiling on an unselected cancer population.
暂无分享,去创建一个
Marian Harris | Ethan Cerami | Frank C Kuo | Levi A Garraway | Paul van Hummelen | William C Hahn | Trevor J Pugh | Joshua D. Campbell | Matthew Meyerson | Lauren L Ritterhouse | Matthew Ducar | Lauren L. Ritterhouse | Bruce E Johnson | Geoffrey R Oxnard | Joshua D Campbell | W. Hahn | M. Meyerson | P. Kantoff | L. Garraway | E. Cerami | B. Rollins | T. Pugh | L. Macconaill | A. Berger | M. Ducar | A. Thorner | M. Harris | J. Christensen | G. Shapiro | A. Ligon | N. Lindeman | D. Kwiatkowski | U. Matulonis | A. Dubuc | S. Ramkissoon | M. Nishino | R. Abo | L. Sholl | G. Oxnard | R. Chao | K. Janeway | Elizabeth P. Garcia | V. Rojas-Rudilla | F. Kuo | K. Do | L. Ritterhouse | Philip W Kantoff | Neal I Lindeman | Ursula Matulonis | Azra H Ligon | Katherine A Janeway | Mizuki Nishino | David J Kwiatkowski | Geoffrey I Shapiro | Vanessa Tassell | Aaron R Thorner | V. Tassell | Barrett J Rollins | Ryan P Abo | Yonghui Jia | Lynette M Sholl | Laura E MacConaill | Vanesa Rojas-Rudilla | Adrian M Dubuc | James M Cleary | Alice H Berger | James Christensen | Khanh Do | Priyanka Shivdasani | Elizabeth P Garcia | Phani Davineni | Alanna Church | Shakti Ramkissoon | Richard Chao | J. Cleary | Priyanka Shivdasani | B. Johnson | A. Church | P. Van Hummelen | Yonghui Jia | J. Campbell | Phani K. Davineni | E. Garcia
[1] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[2] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .
[3] Jae Cheol Lee,et al. Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.
[4] S. Gabriel,et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.
[5] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[6] P. Hammerman,et al. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma , 2016, Clinical Cancer Research.
[7] Michael Bittner,et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Levi A Garraway,et al. Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C. Sander,et al. Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.
[10] W. Hahn,et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. , 2014, The Journal of molecular diagnostics : JMD.
[11] John D Pfeifer,et al. Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data. , 2013, The Journal of molecular diagnostics : JMD.
[12] P. Jänne,et al. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Amber M. Johnson,et al. Clinical next generation sequencing to identify actionable aberrations in a phase I program , 2014, Oncotarget.
[14] Jae Cheol Lee,et al. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. , 2014, Cancer research.
[15] P. D. Dal Cin,et al. Ewing sarcoma mimicking atypical carcinoid tumor: detection of unexpected genomic alterations demonstrates the use of next generation sequencing as a diagnostic tool. , 2014, Cancer genetics.
[16] M. Ladanyi,et al. Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches , 2015, Clinical Cancer Research.
[17] E. Petricoin,et al. A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer , 2014, Breast Cancer Research and Treatment.
[18] Funda Meric-Bernstam,et al. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Redig,et al. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer , 2015, Clinical Cancer Research.
[20] P. Jänne,et al. Clinical Implications of Variant ALK FISH Rearrangement Patterns , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] Nikhil Wagle,et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.
[22] Lisle E. Mose,et al. Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings , 2016, Clinical Cancer Research.
[23] Razelle Kurzrock,et al. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.
[24] B. Crompton,et al. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. , 2016, JAMA oncology.
[25] Dennis C. Friedrich,et al. Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine , 2014 .
[26] Geoffrey R. Oxnard,et al. Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer , 2013, Science Translational Medicine.
[27] M. Kris,et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Mark D. Johnson,et al. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. , 2015, Neuro-oncology.
[29] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] G. Shapiro,et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] R. Kurzrock,et al. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients , 2015, Molecular Cancer Therapeutics.
[32] Nikhil Wagle,et al. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine , 2016, Genome Medicine.
[33] William Pao,et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.
[34] Theresa Zhang,et al. Personalized genomic analyses for cancer mutation discovery and interpretation , 2015, Science Translational Medicine.
[35] P. D. Dal Cin,et al. Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing , 2015, Experimental Hematology & Oncology.
[36] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[37] Vladimir Vacic,et al. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. , 2015, JAMA oncology.
[38] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[39] L. Macconaill,et al. KRAS and NKX2‐1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[40] William Pao,et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. , 2014, The oncologist.
[41] Jane C Weeks,et al. Physicians' attitudes about multiplex tumor genomic testing. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] M. Berger,et al. Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing. , 2013, Journal of visualized experiments : JoVE.
[43] L. Byers,et al. Axl Receptor Axis: A New Therapeutic Target in Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[44] Nicolas Servant,et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.
[45] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[46] P. D. Dal Cin,et al. Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant , 2017, Leukemia & lymphoma.
[47] P. Jänne,et al. Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. , 2015, Cancer research.
[48] Udayan Guha,et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[50] Vladimir Vacic,et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions , 2014, Genome Biology.
[51] Funda Meric-Bernstam,et al. Building a personalized medicine infrastructure at a major cancer center. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[53] M. Mihm,et al. Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas , 2015, Clinical Epigenetics.
[54] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.